Single-center study highlights SOX1 and PAX1 as epigenetic biomarkers in oral squamous cell carcinoma, suggesting future validation is necessary.
Promoter hypermethylation of SOX1 and PAX1 was a frequent event in OSCC, with SOX1 methylation specifically linked to aggressive clinicopathological features and poorer disease-free survival. These findings highlighted SOX1 as a potential prognostic biomarker and PAX1 as a candidate diagnostic marker, warranting further validation in multi-center cohorts to inform epigenetic-targeted strategies in oral oncology.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: